Crossmark

(Arg)9-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling

Crossref DOI link: https://doi.org/10.1186/s13046-018-0812-5

Published Online: 2018-07-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, An-dong

Xu, Hui

Gao, Ya-nan

Luo, Dan-ni

Li, Zhao-feng

Voss, Courtney

Li, Shawn S. C.

Cao, Xuan
Funding

Funding for this research was provided by:

Wuhan Youth Chenguang Program of Science and Technology Foundation (2016070204010100)

Fundamental Research Funds for the Central Universities (HUST:2015YGYL010, HUST: 2016YXMS201)

National Natural Science Foundation of China (Nos. 31571431, 31771541)

Natural Science Foundation of Hubei Province of China (2016CFA053)

Undergraduate Training Programs for Innovation and Entrepreneurship (HUST: jcyxy1705)
License Information

Text and Data Mining valid from 2018-07-05
More Information

Article History

Received: 30 January 2018

Accepted: 2 May 2018

First Online: 5 July 2018

Ethics approval and consent to participate

: All studies involving animals were performed following the National Guides for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.